Advertisement

Dysphagia

pp 1–17 | Cite as

Optimizing the Translational Value of Mouse Models of ALS for Dysphagia Therapeutic Discovery

  • Kate L. Osman
  • Sabrina Kohlberg
  • Alexis Mok
  • Ryan Brooks
  • Lori A. Lind
  • Katelyn McCormack
  • Andries Ferreira
  • Matan Kadosh
  • Mary K. Fagan
  • Elizabeth Bearce
  • Nicole L. Nichols
  • Joan R. Coates
  • Teresa E. LeverEmail author
Original Article

Abstract

The goal of this study was to compare dysphagia phenotypes in low and high copy number (LCN and HCN) transgenic superoxide dismutase 1 (SOD1) mouse models of ALS to accelerate the discovery of novel and effective treatments for dysphagia and early amyotrophic lateral sclerosis (ALS) diagnosis. Clinicopathological features of dysphagia were characterized in individual transgenic mice and age-matched controls utilizing videofluoroscopy in conjunction with postmortem assays of the tongue and hypoglossal nucleus. Quantitative PCR accurately differentiated HCN-SOD1 and LCN-SOD1 mice and nontransgenic controls. All HCN-SOD1 mice developed stereotypical paralysis in both hindlimbs. In contrast, LCN-SOD1 mice displayed wide variability in fore- and hindlimb involvement. Lick rate, swallow rate, inter-swallow interval, and pharyngeal transit time were significantly altered in both HCN-SOD1 and LCN-SOD1 mice compared to controls. Tongue weight, tongue dorsum surface area, total tongue length, and caudal tongue length were significantly reduced only in the LCN-SOD1 mice compared to age-matched controls. LCN-SOD1 mice with lower body weights had smaller/lighter weight tongues, and those with forelimb paralysis and slower lick rates died at a younger age. LCN-SOD1 mice had a 32% loss of hypoglossal neurons, which differed significantly when compared to age-matched control mice. These novel findings for LCN-SOD1 mice are congruent with reported dysphagia and associated tongue atrophy and hypoglossal nucleus pathology in human ALS patients, thus highlighting the translational potential of this mouse model in ALS research.

Keywords

Deglutition Deglutition disorders Dysphagia Amyotrophic lateral sclerosis (ALS) Superoxide dismutase 1 (SOD1) transgenic mouse Videofluoroscopy 

Notes

Acknowledgements

We graciously thank the numerous students affiliated with the Lever Lab who assisted with VFSS analysis (Kaitlin Flynn, Dana Aleman, Mitchell Allen, Victoria Caywood, Loren Littrell, Rebecca Harris Healy, Mollie Ulsas, and Elizabeth White) and histology (Iyas Daghlas, Abby Lind, Chandler DeJonge, Victoria Rufo, and Michaela Thomson).

Funding

This study was funded in part by two grants from the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health (Award Numbers R03 DC0110895 and R21 DC016071; T.E. Lever), University of Missouri Research Board Grant (T.E. Lever and N.L. Nichols), and Mizzou Advantage Seed Funding (T.E. Lever and J.R. Coates). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving Human Participants and/or Animals

No human participants were included in this study; only animals. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

References

  1. 1.
    Ertekin C, Aydogdu I, Yuceyar N, Kiylioglu N, Tarlaci S, Uludag B. Pathophysiological mechanisms of oropharyngeal dysphagia in amyotrophic lateral sclerosis. Brain. 2000;123(Pt 1):125–40.Google Scholar
  2. 2.
    Hadjikoutis S, Wiles CM. Respiratory complications related to bulbar dysfunction in motor neuron disease. Acta Neurol Scand. 2001;103(4):207–13.Google Scholar
  3. 3.
    Higo R, Tayama N, Watanabe T, Nitou T. Videomanofluorometric study in amyotrophic lateral sclerosis. Laryngoscope. 2002;112(5):911–7.Google Scholar
  4. 4.
    Hillel AD, Miller RM. Management of bulbar symptoms in amyotrophic lateral sclerosis. Adv Exp Med Biol. 1987;209:201–21.Google Scholar
  5. 5.
    Kawai S, Tsukuda M, Mochimatsu I, Enomoto H, Kagesato Y, Hirose H, Kuroiwa Y, Suzuki Y. A study of the early stage of dysphagia in amyotrophic lateral sclerosis. Dysphagia. 2003;18(1):1–8.Google Scholar
  6. 6.
    Tayama N. Dysphagia in amyotrophic lateral sclerosis—the mechanism and managements. Rinsho Shinkeigaku. 1995;35(12):1557–9.Google Scholar
  7. 7.
    Kuhnlein P, Gdynia HJ, Sperfeld AD, Lindner-Pfleghar B, Ludolph AC, Prosiegel M, Riecker A. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008;4(7):366–74.Google Scholar
  8. 8.
    Shigemitsu H, Afshar K. Aspiration pneumonias: under-diagnosed and under-treated. Curr Opin Pulm Med. 2007;13(3):192–8.Google Scholar
  9. 9.
    Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942–55.  https://doi.org/10.1016/S0140-6736(10)61156-7.Google Scholar
  10. 10.
    Leder SB, Novella S, Patwa H. Use of fiberoptic endoscopic evaluation of swallowing (FEES) in patients with amyotrophic lateral sclerosis. Dysphagia. 2004;19(3):177–81.Google Scholar
  11. 11.
    Sandyk R. Serotonergic mechanisms in amyotrophic lateral sclerosis. Int J Neurosci. 2006;116(7):775–826.  https://doi.org/10.1080/00207450600754087.Google Scholar
  12. 12.
    Wright R, Jordan C. Videofluoroscopic evaluation of dysphagia in motor neurone disease with modified barium swallow. Palliat Med. 1997;11(1):44–8.Google Scholar
  13. 13.
    DePaul R, Abbs JH, Caligiuri M, Gracco VL, Brooks BR. Hypoglossal, trigeminal, and facial motoneuron involvement in amyotrophic lateral sclerosis. Neurology. 1988;38(2):281–3.Google Scholar
  14. 14.
    DePaul R, Brooks BR. Multiple orofacial indices in amyotrophic lateral sclerosis. J Speech Hear Res. 1993;36(6):1158–67.Google Scholar
  15. 15.
    Dworkin JP. Tongue strength measurement in patients with amyotrophic lateral sclerosis: qualitative vs quantitative procedures. Arch Phys Med Rehabil. 1980;61(9):422–4.Google Scholar
  16. 16.
    Weikamp JG, Schelhaas HJ, Hendriks JC, de Swart BJ, Geurts AC. Prognostic value of decreased tongue strength on survival time in patients with amyotrophic lateral sclerosis. J Neurol. 2012;259(11):2360–5.  https://doi.org/10.1007/s00415-012-6503-9.Google Scholar
  17. 17.
    Umemoto G, Furuya H, Tsuboi Y, Fujioka S, Arahata H, Sugahara M, Sakai M. Characteristics of tongue and pharyngeal pressure in patients with neuromuscular diseases. Degener Neurol Neuromuscul Dis. 2017;7:71–8.  https://doi.org/10.2147/DNND.S132745.Google Scholar
  18. 18.
    Hillel AD, Miller R. Bulbar amyotrophic lateral sclerosis: patterns of progression and clinical management. Head Neck. 1989;11(1):51–9.Google Scholar
  19. 19.
    Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264(5166):1772–5.Google Scholar
  20. 20.
    Tu PH, Raju P, Robinson KA, Gurney ME, Trojanowski JQ, Lee VM. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA. 1996;93(7):3155–60.Google Scholar
  21. 21.
    Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39(2):147–57.  https://doi.org/10.1002/ana.410390203.Google Scholar
  22. 22.
    Pfohl SR, Halicek MT, Mitchell CS. Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: a meta-analysis. J Neuromuscul Dis. 2015;2(2):137–50.  https://doi.org/10.3233/JND-140068.Google Scholar
  23. 23.
    Daghlas I, Schmittdiel T, Martin H, Kadosh K, Goding G, Mancini S, Dougherty D, Harris K, Robbins K, Lever T. Effects of gene copy number on dysphagia onset in SOD1-G93A transgenic mice. Amyotroph Later Scler Frontotemp Degener. 2015;16:217–26.  https://doi.org/10.3109/21678421.2015.1098818/0016.Google Scholar
  24. 24.
    Acevedo-Arozena A, Kalmar B, Essa S, Ricketts T, Joyce P, Kent R, Rowe C, Parker A, Gray A, Hafezparast M, Thorpe JR, Greensmith L, Fisher EM. A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis Model Mech. 2011;4(5):686–700.  https://doi.org/10.1242/dmm.007237.Google Scholar
  25. 25.
    Dal Canto M, Gurney M. A low expressor line of transgenic mice carrying a mutant human Cu, Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathol. 1997;93:537–50.Google Scholar
  26. 26.
    Shibata N. Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathology. 2001;21(1):82–92.Google Scholar
  27. 27.
    Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, Blankenhorn EP, Heiman-Patterson TD. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res. 2004;130(1–2):7–15.Google Scholar
  28. 28.
    JAX Mice Database. 2014. https://www.jax.org/strain/002300. Accessed 3 Nov 2019.
  29. 29.
    Jaarsma D, Teuling E, Haasdijk E, De Zeeuw C, Hoogenraad C. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci. 2008;28(9):2075–88.Google Scholar
  30. 30.
    Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci. 1997;152(Suppl 1):S67–73.Google Scholar
  31. 31.
    Lever T, Brooks R, Thombs L, Littrell L, Harris R, Allen M, Kadosh M, Robbins K. Videofluoroscopic validation of a translational murine model of presbyphagia. Dysphagia. 2015;30:328.Google Scholar
  32. 32.
    Lever TE, Braun SM, Brooks RT, Harris RA, Littrell LL, Neff RM, Hinkel CJ, Allen MJ, Ulsas MA. Adapting human videofluoroscopic swallow study methods to detect and characterize dysphagia in murine disease models. J Vis Exp. 2015;97:e52319.  https://doi.org/10.3791/52319.Google Scholar
  33. 33.
    Achilli F, Boyle S, Kieran D, Chia R, Hafezparast M, Martin JE, Schiavo G, Greensmith L, Bickmore W, Fisher EM. The SOD1 transgene in the G93A mouse model of amyotrophic lateral sclerosis lies on distal mouse chromosome 12. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(2):111–4.  https://doi.org/10.1080/14660820510035351.Google Scholar
  34. 34.
    The Jackson Laboratory, editor. Breeding strategies for maintaining colonies of laboratory mice. Bar Harbor: TJ Laboratory; 2009.Google Scholar
  35. 35.
    Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. 2002;30(6):503–12.Google Scholar
  36. 36.
    D’Haene B, Vandesompele J, Hellemans J. Accurate and objective copy number profiling using real-time quantitative PCR. Methods (San Diego, Calif). 2010;50(4):262–70.  https://doi.org/10.1016/j.ymeth.2009.12.007.Google Scholar
  37. 37.
    Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale. Dysphagia. 1996;11(2):93–8.Google Scholar
  38. 38.
    Reiner DJ, Jan TA, Boughter JD Jr, Li CX, Lu L, Williams RW, Waters RS. Genetic analysis of tongue size and taste papillae number and size in recombinant inbred strains of mice. Chem Sens. 2008;33(8):693–707.  https://doi.org/10.1093/chemse/bjn025.Google Scholar
  39. 39.
    Salas M, Rubio L, Torrero C, Carreon M, Regalado M. Effects of perinatal undernutrition on the circumvallate papilla of developing Wistar rats. Acta Histochem. 2016;118(6):581–7.  https://doi.org/10.1016/j.acthis.2016.06.003.Google Scholar
  40. 40.
    Paxinos G, Franklin K. The mouse brain in stereotaxic coordinates. 4th ed. Cambridge: Academic Press; 2013.Google Scholar
  41. 41.
    Paxinos G, Franklin K. The mouse brain in sterotaxic coordinates. 2nd ed. Sidney: Academic Press; 2001.Google Scholar
  42. 42.
    Ferrucci M, Spalloni A, Bartalucci A, Cantafora E, Fulceri F, Nutini M, Longone P, Paparelli A, Fornai F. A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium. Neurobiol Dis. 2010;37(2):370–83.Google Scholar
  43. 43.
    Haenggeli C, Kato AC. Differential vulnerability of cranial motoneurons in mouse models with motor neuron degeneration. Neurosci Lett. 2002;335(1):39–43.Google Scholar
  44. 44.
    Sasaki S, Warita H, Abe K, Iwata M. Slow component of axonal transport is impaired in the proximal axon of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol. 2004;107(5):452–60.  https://doi.org/10.1007/s00401-004-0838-y.Google Scholar
  45. 45.
    Higo R, Tayama N, Nito T. Longitudinal analysis of progression of dysphagia in amyotrophic lateral sclerosis. Auris Nasus Larynx. 2004;31(3):247–54.  https://doi.org/10.1016/j.anl.2004.05.009.Google Scholar
  46. 46.
    Cha CH, Patten BM. Amyotrophic lateral sclerosis: abnormalities of the tongue on magnetic resonance imaging. Ann Neurol. 1989;25(5):468–72.  https://doi.org/10.1002/ana.410250508.Google Scholar
  47. 47.
    Morimoto N, Yamashita T, Sato K, Kurata T, Ikeda Y, Kusuhara T, Murata N, Abe K. Assessment of swallowing in motor neuron disease and Asidan/SCA36 patients with new methods. J Neurol Sci. 2013;324(1–2):149–55.  https://doi.org/10.1016/j.jns.2012.10.025.Google Scholar
  48. 48.
    Kiernan JA, Hudson AJ. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain. 1991;114(Pt 2):843–53.Google Scholar
  49. 49.
    Waito AA, Tabor-Gray LC, Steele CM, Plowman EK. Reduced pharyngeal constriction is associated with impaired swallowing efficiency in amyotrophic lateral sclerosis (ALS). Neurogastroenterol Motil. 2018;30(12):e13450.  https://doi.org/10.1111/nmo.13450.Google Scholar
  50. 50.
    Paris G, Martinaud O, Petit A, Cuvelier A, Hannequin D, Roppeneck P, Verin E. Oropharyngeal dysphagia in amyotrophic lateral sclerosis alters quality of life. J Oral Rehabil. 2013;40(3):199–204.  https://doi.org/10.1111/joor.12019.Google Scholar
  51. 51.
    Lever TE, Gorsek A, Cox KT, O’Brien KF, Capra NF, Hough MS, Murashov AK. An animal model of oral dysphagia in amyotrophic lateral sclerosis. Dysphagia. 2009;24(2):180–95.  https://doi.org/10.1007/s00455-008-9190-z.Google Scholar
  52. 52.
    Smittkamp SE, Brown JW, Stanford JA. Time-course and characterization of orolingual motor deficits in B6SJL-Tg(SOD1-G93A)1Gur/J mice. Neuroscience. 2008;151(2):613–21.  https://doi.org/10.1016/j.neuroscience.2007.10.017.Google Scholar
  53. 53.
    van Zundert B, Peuscher MH, Hynynen M, Chen A, Neve RL, Brown RH Jr, Constantine-Paton M, Bellingham MC. Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Neurosci. 2008;28(43):10864–74.Google Scholar
  54. 54.
    Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723–49.  https://doi.org/10.1146/annurev.neuro.27.070203.144244.Google Scholar
  55. 55.
    Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, Floeter MK, Henderson C, Lomen-Hoerth C, Macklis JD, McCluskey L, Mitsumoto H, Przedborski S, Rothstein J, Trojanowski JQ, van den Berg LH, Ringel S. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Later Scler Frontotemp Degener. 2013;14(Suppl 1):5–18.  https://doi.org/10.3109/21678421.2013.778548.Google Scholar
  56. 56.
    Walhout R, Verstraete E, van den Heuvel MP, Veldink JH, van den Berg LH. Patterns of symptom development in patients with motor neuron disease. Amyotroph Later Scler Frontotemp Degener. 2018;19(1–2):21–8.  https://doi.org/10.1080/21678421.2017.1386688.Google Scholar
  57. 57.
    Christensen PB, Hojer-Pedersen E, Jensen NB. Survival of patients with amyotrophic lateral sclerosis in 2 Danish counties. Neurology. 1990;40(4):600–4.Google Scholar
  58. 58.
    del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60(5):813–9.Google Scholar
  59. 59.
    Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25(5):709–14.  https://doi.org/10.1002/mus.10090.Google Scholar
  60. 60.
    Rosen AD. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol. 1978;35(10):638–42.Google Scholar
  61. 61.
    Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Later Scler Other Motor Neuron Disord. 2004;5(4):208–12.Google Scholar
  62. 62.
    Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3:17071.  https://doi.org/10.1038/nrdp.2017.71.Google Scholar
  63. 63.
    Corcia P, Pradat PF, Salachas F, Bruneteau G, Forestier N, Seilhean D, Hauw JJ, Meininger V. Causes of death in a post-mortem series of ALS patients. Amyotroph Later Scler. 2008;9(1):59–62.Google Scholar
  64. 64.
    Sejvar JJ, Holman RC, Bresee JS, Kochanek KD, Schonberger LB. Amyotrophic lateral sclerosis mortality in the United States, 1979–2001. Neuroepidemiology. 2005;25(3):144–52.Google Scholar
  65. 65.
    Spataro R, Lo Re M, Piccoli T, Piccoli F, La Bella V. Causes and place of death in Italian patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2010;122(3):217–23.Google Scholar
  66. 66.
    Brooks BR, Sanjak M. Disease-modifying drug therapies. Amyotroph Later Scler Other Motor Neuron Disord. 2004;5(Suppl 1):68–75.  https://doi.org/10.1080/17434470410019898.Google Scholar
  67. 67.
    Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, Delumeau JC, Meininger V. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole study group-II. Neurology. 1996;47(6 Suppl 4):S242–50.Google Scholar
  68. 68.
    Orsini M, Oliveira AB, Nascimento OJ, Reis CH, Leite MA, de Souza JA, Pupe C, de Souza OG, Bastos VH, de Freitas MR, Teixeira S, Bruno C, Davidovich E, Smidt B. Amyotrophic lateral sclerosis: new perpectives and update. Neurol Int. 2015;7(2):5885.  https://doi.org/10.4081/ni.2015.5885.Google Scholar
  69. 69.
    Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007;1:CD001447.  https://doi.org/10.1002/14651858.cd001447.pub2.Google Scholar
  70. 70.
    Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:001447.  https://doi.org/10.1002/14651858.cd001447.pub3.Google Scholar
  71. 71.
    Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–12.  https://doi.org/10.1016/S1474-4422(17)30115-1.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Kate L. Osman
    • 1
  • Sabrina Kohlberg
    • 1
  • Alexis Mok
    • 1
  • Ryan Brooks
    • 1
  • Lori A. Lind
    • 2
  • Katelyn McCormack
    • 1
  • Andries Ferreira
    • 1
  • Matan Kadosh
    • 1
  • Mary K. Fagan
    • 3
  • Elizabeth Bearce
    • 1
  • Nicole L. Nichols
    • 2
  • Joan R. Coates
    • 4
  • Teresa E. Lever
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Otolaryngology – Head and Neck SurgeryUniversity of Missouri School of MedicineColumbiaUSA
  2. 2.Department of Biomedical SciencesUniversity of Missouri College of Veterinary MedicineColumbiaUSA
  3. 3.Department of Communication Science and DisordersUniversity of Missouri School of Health ProfessionsColumbiaUSA
  4. 4.Department of Veterinary Medicine and SurgeryUniversity of Missouri College of Veterinary MedicineColumbiaUSA

Personalised recommendations